188 related articles for article (PubMed ID: 23936614)
1. Xenobiotic sensor- and metabolism-related gene variants in environmental sensitivity-related illnesses: a survey on the Italian population.
Caccamo D; Cesareo E; Mariani S; Raskovic D; Ientile R; Currò M; Korkina L; De Luca C
Oxid Med Cell Longev; 2013; 2013():831969. PubMed ID: 23936614
[TBL] [Abstract][Full Text] [Related]
2. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.
Arvanitidis K; Ragia G; Iordanidou M; Kyriaki S; Xanthi A; Tavridou A; Manolopoulos VG
Fundam Clin Pharmacol; 2007 Aug; 21(4):419-26. PubMed ID: 17635181
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.
Gaikovitch EA; Cascorbi I; Mrozikiewicz PM; Brockmöller J; Frötschl R; Köpke K; Gerloff T; Chernov JN; Roots I
Eur J Clin Pharmacol; 2003 Aug; 59(4):303-12. PubMed ID: 12879168
[TBL] [Abstract][Full Text] [Related]
5. Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus.
Semiz S; Dujic T; Ostanek B; Prnjavorac B; Bego T; Malenica M; Marc J; Causevic A
Bosn J Basic Med Sci; 2010 Nov; 10(4):287-91. PubMed ID: 21108610
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome p450 polymorphisms in geriatric patients: impact on adverse drug reactions--a pilot study.
Egger T; Dormann H; Ahne G; Pahl A; Runge U; Azaz-Livshits T; Neubert A; Criegee-Rieck M; Gassmann KG; Brune K
Drugs Aging; 2005; 22(3):265-72. PubMed ID: 15813658
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales.
Sistonen J; Fuselli S; Palo JU; Chauhan N; Padh H; Sajantila A
Pharmacogenet Genomics; 2009 Feb; 19(2):170-9. PubMed ID: 19151603
[TBL] [Abstract][Full Text] [Related]
9. Microarray-based detection of CYP1A1, CYP2C9, CYP2C19, CYP2D6, GSTT1, GSTM1, MTHFR, MTRR, NQO1, NAT2, HLA-DQA1, and AB0 allele frequencies in native Russians.
Gra O; Mityaeva O; Berdichevets I; Kozhekbaeva Z; Fesenko D; Kurbatova O; Goldenkova-Pavlova I; Nasedkina T
Genet Test Mol Biomarkers; 2010 Jun; 14(3):329-42. PubMed ID: 20373852
[TBL] [Abstract][Full Text] [Related]
10. Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics.
Kirchheiner J; Müller G; Meineke I; Wernecke KD; Roots I; Brockmöller J
J Clin Psychopharmacol; 2003 Oct; 23(5):459-66. PubMed ID: 14520122
[TBL] [Abstract][Full Text] [Related]
11. Polymorphic drug metabolizing CYP-enzymes--a pathogenic factor in oral lichen planus?
Kragelund C; Hansen C; Reibel J; Nauntofte B; Broesen K; Pedersen AM; Smidt D; Eiberg H; Torpet LA
J Oral Pathol Med; 2009 Jan; 38(1):63-71. PubMed ID: 19192051
[TBL] [Abstract][Full Text] [Related]
12. Assessment of CYP2C9, CYP2C19, and CYP2D6 Polymorphisms in Allergic Patients with Chemical Sensitivity.
D'Attis S; Massari S; Mazzei F; Maio D; Vergallo I; Mauro S; Minelli M; Bozzetti MP
Int Arch Allergy Immunol; 2019; 179(3):173-186. PubMed ID: 30943525
[TBL] [Abstract][Full Text] [Related]
13. The effect of genetic polymorphisms of cytochrome P450 CYP2C9, CYP2C19, and CYP2D6 on drug-resistant epilepsy in Turkish children.
Seven M; Batar B; Unal S; Yesil G; Yuksel A; Guven M
Mol Diagn Ther; 2014 Apr; 18(2):229-36. PubMed ID: 24338437
[TBL] [Abstract][Full Text] [Related]
14. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
15. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.
Scordo MG; Spina E; Dahl ML; Gatti G; Perucca E
Basic Clin Pharmacol Toxicol; 2005 Nov; 97(5):296-301. PubMed ID: 16236141
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations.
Zuo J; Xia D; Jia L; Guo T
Pharmazie; 2012 Jul; 67(7):639-44. PubMed ID: 22888523
[TBL] [Abstract][Full Text] [Related]
17. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.
Halling J; Petersen MS; Damkier P; Nielsen F; Grandjean P; Weihe P; Lundgren S; Lundblad MS; Brøsen K
Eur J Clin Pharmacol; 2005 Aug; 61(7):491-7. PubMed ID: 16025294
[TBL] [Abstract][Full Text] [Related]
18. Biological definition of multiple chemical sensitivity from redox state and cytokine profiling and not from polymorphisms of xenobiotic-metabolizing enzymes.
De Luca C; Scordo MG; Cesareo E; Pastore S; Mariani S; Maiani G; Stancato A; Loreti B; Valacchi G; Lubrano C; Raskovic D; De Padova L; Genovesi G; Korkina LG
Toxicol Appl Pharmacol; 2010 Nov; 248(3):285-92. PubMed ID: 20430047
[TBL] [Abstract][Full Text] [Related]
19. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.
Kirchheiner J; Meineke I; Müller G; Roots I; Brockmöller J
Pharmacogenetics; 2002 Oct; 12(7):571-80. PubMed ID: 12360109
[TBL] [Abstract][Full Text] [Related]
20. Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in aborigines from western Australia.
Griese EU; Ilett KF; Kitteringham NR; Eichelbaum M; Powell H; Spargo RM; LeSouef PN; Musk AW; Minchin RF
Pharmacogenetics; 2001 Feb; 11(1):69-76. PubMed ID: 11207032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]